LTGO
Latigo Biotherapeutics, Inc.
Price Chart
Latest Quote
$15.21
-0.05 (-0.33%)
Current Price
| Previous Close | $15.26 |
| Open | $15.33 |
| Day High | $15.86 |
| Day Low | $15.01 |
| Volume | 164,098 |
Stock Information
| Shares Outstanding | 66.30M |
| Total Debt | $31.25M |
| Cash Equivalents | $55.00M |
| Net Income | $-111.14M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.01B |
| EPS (TTM) | $-2.52 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.27B |
| Income | $-111.14M |
| Book/sh | $-279.37 |
| Cash/sh | $0.83 |
| Employees | 66 |
Financial Ratios
| Quick Ratio | 1.07 |
| Current Ratio | 1.15 |
| Debt/Eq | 249.96 |
Returns & Margins
Ownership
| Insider Ownership | 4.98% |
| Institutional Ownership | 80.73% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -7.28 |
| P/B | -0.05 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $52.25 |
Technical Indicators
| SMA20 | $15.55 |
| SMA50 | $19.26 |
| RSI | 48.44 |
| ATR | 1.2757 |
| Shares Float | 21.74M |
| Short Ratio | 1.91 |
| Rel Volume | 0.61 |
Performance History
| Week | -0.26% |
| Month | -12.99% |
| YTD | -16.66% |
| 10 Years | -16.66% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $15.21 | 164,100 |
| 2026-10-26 | $15.26 | 165,300 |
| 2026-10-23 | $15.02 | 146,000 |
| 2026-10-22 | $16.57 | 119,400 |
| 2026-10-21 | $16.34 | 173,800 |
| 2026-10-20 | $15.25 | 147,800 |
| 2026-10-19 | $14.30 | 283,800 |
| 2026-10-16 | $14.00 | 207,400 |
| 2026-10-15 | $14.76 | 242,900 |
| 2026-10-14 | $14.00 | 220,600 |
| 2026-10-13 | $15.71 | 346,800 |
| 2026-10-12 | $16.02 | 133,000 |
| 2026-10-09 | $16.00 | 184,200 |
| 2026-10-08 | $14.79 | 265,100 |
| 2026-10-07 | $15.52 | 241,500 |
| 2026-10-06 | $16.26 | 544,500 |
| 2026-10-05 | $16.63 | 590,000 |
| 2026-10-02 | $15.90 | 276,600 |
| 2026-10-01 | $16.69 | 436,700 |
| 2026-09-30 | $16.70 | 532,600 |
| 2026-09-29 | $18.10 | 955,200 |
| 2026-09-28 | $17.48 | 260,300 |
About Latigo Biotherapeutics, Inc.
Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis; and LTG-418, a NaV1.8 inhibitor developed for the treatment of acute and chronic pain. Latigo Biotherapeutics, Inc. was formerly known as WVB-Desmond, Inc. and changed its name to Latigo Biotherapeutics, Inc. in March 2019. Latigo Biotherapeutics, Inc. was incorporated in 2018 and is based in Thousand Oaks, California.
đ° Latest News
No news articles available at the moment. Check back later for updates on LTGO.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue | ||
| Total Revenue | $0 | $0 |
| Operating Revenue | $0 | $0 |
| Expenses | ||
| Total Expenses | $110,392,000 | $63,451,000 |
| Other Income Expense | $-1,718,000 | $4,000 |
| Other Non Operating Income Expenses | $-1,718,000 | $4,000 |
| Net Non Operating Interest Income Expense | $2,943,000 | $2,264,000 |
| Operating Expense | $110,392,000 | $63,451,000 |
| General And Administrative Expense | $10,862,000 | $6,667,000 |
| Income & Earnings | ||
| Net Income From Continuing Operation Net Minority Interest | $-109,167,000 | $-61,183,000 |
| Net Interest Income | $2,943,000 | $2,264,000 |
| Interest Income | $2,943,000 | $2,264,000 |
| Normalized Income | $-109,167,000 | $-61,183,000 |
| Net Income From Continuing And Discontinued Operation | $-109,167,000 | $-61,183,000 |
| Total Operating Income As Reported | $-110,392,000 | $-63,451,000 |
| Net Income Common Stockholders | $-109,167,000 | $-61,183,000 |
| Net Income | $-109,167,000 | $-61,183,000 |
| Net Income Including Noncontrolling Interests | $-109,167,000 | $-61,183,000 |
| Net Income Continuous Operations | $-109,167,000 | $-61,183,000 |
| Pretax Income | $-109,167,000 | $-61,183,000 |
| Interest Income Non Operating | $2,943,000 | $2,264,000 |
| Operating Income | $-110,392,000 | $-63,451,000 |
| Per Share | ||
| Diluted EPS | $-2.48 | $-1.39 |
| Basic EPS | $-2.48 | $-1.39 |
| Other | ||
| Tax Effect Of Unusual Items | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-110,143,000 | $-63,207,000 |
| Reconciled Depreciation | $249,000 | $244,000 |
| EBITDA (Bullshit earnings) | $-110,143,000 | $-63,207,000 |
| EBIT | $-110,392,000 | $-63,451,000 |
| Diluted Average Shares | $43,958,000 | $44,022,000 |
| Basic Average Shares | $43,958,000 | $44,022,000 |
| Diluted NI Availto Com Stockholders | $-109,167,000 | $-61,183,000 |
| Research And Development | $99,530,000 | $56,784,000 |
| Selling General And Administration | $10,862,000 | $6,667,000 |
| Other Gand A | $3,691,000 | $2,476,000 |
| Salaries And Wages | $7,171,000 | $4,191,000 |
Fetched: 2026-10-14
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Assets | ||
| Net Tangible Assets | $-231,674,000 | $-129,599,000 |
| Total Assets | $75,516,000 | $22,864,000 |
| Total Non Current Assets | $1,687,000 | $1,700,000 |
| Other Non Current Assets | $616,000 | $290,000 |
| Current Assets | $73,829,000 | $21,164,000 |
| Restricted Cash | $192,000 | $0 |
| Prepaid Assets | $4,200,000 | $3,246,000 |
| Cash Cash Equivalents And Short Term Investments | $69,437,000 | $17,918,000 |
| Cash And Cash Equivalents | $69,437,000 | $17,918,000 |
| Debt | ||
| Total Debt | $690,000 | $851,000 |
| Long Term Debt And Capital Lease Obligation | $127,000 | $464,000 |
| Current Debt And Capital Lease Obligation | $563,000 | $387,000 |
| Liabilities | ||
| Total Liabilities Net Minority Interest | $307,190,000 | $152,463,000 |
| Total Non Current Liabilities Net Minority Interest | $288,744,000 | $138,028,000 |
| Other Non Current Liabilities | $35,000 | $35,000 |
| Current Liabilities | $18,446,000 | $14,435,000 |
| Payables And Accrued Expenses | $13,680,000 | $11,774,000 |
| Payables | $5,015,000 | $7,068,000 |
| Accounts Payable | $5,015,000 | $7,068,000 |
| Other Current Liabilities | - | $250,000 |
| Equity | ||
| Common Stock Equity | $-231,674,000 | $-129,599,000 |
| Total Equity Gross Minority Interest | $-231,674,000 | $-129,599,000 |
| Stockholders Equity | $-231,674,000 | $-129,599,000 |
| Retained Earnings | $-243,131,000 | $-133,964,000 |
| Preferred Securities Outside Stock Equity | $288,582,000 | $137,529,000 |
| Other | ||
| Ordinary Shares Number | $60,153,191 | $60,153,191 |
| Share Issued | $60,153,191 | $60,153,191 |
| Tangible Book Value | $-231,674,000 | $-129,599,000 |
| Invested Capital | $-231,674,000 | $-129,599,000 |
| Working Capital | $55,383,000 | $6,729,000 |
| Capital Lease Obligations | $690,000 | $851,000 |
| Total Capitalization | $-231,674,000 | $-129,599,000 |
| Additional Paid In Capital | $11,457,000 | $4,365,000 |
| Capital Stock | $0 | $0 |
| Common Stock | $0 | $0 |
| Long Term Capital Lease Obligation | $127,000 | $464,000 |
| Current Capital Lease Obligation | $563,000 | $387,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $4,203,000 | $2,024,000 |
| Current Accrued Expenses | $8,665,000 | $4,706,000 |
| Net PPE | $1,071,000 | $1,410,000 |
| Accumulated Depreciation | $-854,000 | $-605,000 |
| Gross PPE | $1,925,000 | $2,015,000 |
| Other Properties | $1,825,000 | $1,949,000 |
| Machinery Furniture Equipment | $100,000 | $66,000 |
Fetched: 2026-10-14
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Free Cash Flow | ||
| Free Cash Flow | $-97,693,000 | $-51,027,000 |
| Operating Activities | ||
| Operating Cash Flow | $-97,557,000 | $-50,955,000 |
| Cash Flow From Continuing Operating Activities | $-97,557,000 | $-50,955,000 |
| Investing Activities | ||
| Capital Expenditure | $-136,000 | $-72,000 |
| Investing Cash Flow | $-136,000 | $-72,000 |
| Cash Flow From Continuing Investing Activities | $-136,000 | $-72,000 |
| Financing Activities | ||
| Issuance Of Capital Stock | $149,379,000 | $337,000 |
| Financing Cash Flow | $149,496,000 | $607,000 |
| Cash Flow From Continuing Financing Activities | $149,496,000 | $607,000 |
| Net Preferred Stock Issuance | $149,379,000 | $0 |
| Preferred Stock Issuance | $149,379,000 | $0 |
| Net Common Stock Issuance | $0 | $337,000 |
| Common Stock Issuance | $0 | $337,000 |
| Other | ||
| End Cash Position | $69,721,000 | $17,918,000 |
| Beginning Cash Position | $17,918,000 | $68,338,000 |
| Changes In Cash | $51,803,000 | $-50,420,000 |
| Proceeds From Stock Option Exercised | $117,000 | $270,000 |
| Net PPE Purchase And Sale | $-136,000 | $-72,000 |
| Purchase Of PPE | $-136,000 | $-72,000 |
| Change In Working Capital | $2,518,000 | $6,887,000 |
| Change In Other Current Liabilities | $-446,000 | $-352,000 |
| Change In Other Current Assets | $-234,000 | $98,000 |
| Change In Payables And Accrued Expense | $4,177,000 | $9,300,000 |
| Change In Accrued Expense | $6,138,000 | $3,548,000 |
| Change In Payable | $-1,961,000 | $5,752,000 |
| Change In Account Payable | $-1,961,000 | $5,752,000 |
| Change In Prepaid Assets | $-979,000 | $-2,159,000 |
| Other Non Cash Items | $444,000 | $327,000 |
| Stock Based Compensation | $6,725,000 | $2,770,000 |
| Unrealized Gain Loss On Investment Securities | $1,674,000 | $0 |
| Depreciation Amortization Depletion | $249,000 | $244,000 |
| Depreciation And Amortization | $249,000 | $244,000 |
| Depreciation | $249,000 | $244,000 |
| Net Income From Continuing Operations | $-109,167,000 | $-61,183,000 |
Fetched: 2026-10-14